04Oct 2021
A randomized clinical trial on the short‐term effects of 12 weeks sacubitril/valsartan versus enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: Results from the ACTIVITY‐HF study

A randomized clinical trial on the short‐term effects of 12 weeks sacubitril/valsartan versus enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: Results from the ACTIVITY‐HF study

ACTIVITY‐HF was a randomized, double‐blind, active‐controlled study, which assessed the short‐term effect of sacubitril/valsartan compared with the active‐comparator enalapril on improving maximal exercise capacity in patients with heart failure with reduced ejection fraction (HFrEF). Short‐term treatment with sacubitril/valsartan for 12 weeks did not result in significant benefits on peak VO2 when compared with enalapril.

  • #family health

Like

Save

Share